当前位置: X-MOL 学术JAMA Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial.
JAMA Neurology ( IF 29.0 ) Pub Date : 2023-05-08 , DOI: 10.1001/jamaneurol.2023.0997
Daniele Altomare 1, 2, 3 , Frederik Barkhof 4, 5 , Camilla Caprioglio 1, 2 , Lyduine E Collij 4 , Philip Scheltens 6 , Isadora Lopes Alves 4 , Femke Bouwman 6 , Johannes Berkhof 7 , Ingrid S van Maurik 6, 7 , Valentina Garibotto 8, 9 , Christian Moro 1, 2 , Julien Delrieu 10, 11 , Pierre Payoux 12, 13 , Laure Saint-Aubert 12, 13 , Anne Hitzel 12 , José Luis Molinuevo 14, 15 , Oriol Grau-Rivera 14, 16, 17 , Juan Domingo Gispert 14, 16, 18 , Alexander Drzezga 19, 20, 21 , Frank Jessen 20, 22, 23 , Philip Zeyen 22 , Agneta Nordberg 24, 25 , Irina Savitcheva 26 , Vesna Jelic 27 , Zuzana Walker 28, 29 , Paul Edison 30 , Jean-François Demonet 31 , Rossella Gismondi 32 , Gill Farrar 33 , Andrew W Stephens 32 , Giovanni B Frisoni 1, 2 ,
Affiliation  

Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect.

中文翻译:

记忆门诊患者早期与晚期淀粉样蛋白正电子发射断层扫描的临床效果:AMYPAD-DPMS 随机临床试验。

淀粉样蛋白正电子发射断层扫描 (PET) 可以直接评估淀粉样蛋白沉积,这是阿尔茨海默病的主要标志之一。然而,由于缺乏适当设计的研究证明其临床效果,该技术目前未得到广泛报销。
更新日期:2023-05-08
down
wechat
bug